Document is current
Any future updates will be listed below
-
Authors
Järvelä-Reijonen, Elina
Järvinen, Suvi https://orcid.org/0000-0002-0043-9860
Karhunen, Leila
Föhr, Tiina
Myllymäki, Tero
Sairanen, Essi
Lindroos, Sanni
Peuhkuri, Katri
Hallikainen, Maarit
Pihlajamäki, Jussi
Puttonen, Sampsa
Korpela, Riitta
Ermes, Miikka
Lappalainen, Raimo
Kujala, Urho M.
Kolehmainen, Marjukka
Laitinen, Jaana
-
Funding
Funding for this research was provided by:
Tekes (1104/10)
Strategic Research Council (303430)
Business Finland (2726/31/2014)
Academy of Finland (286028)
Pohjois-Savon Rahasto
- License Information
-
More Information
Article History
Received: 13 December 2020
Accepted: 8 June 2021
First Online: 28 June 2021
Declarations
:
: The ethics committee of the Central Finland Health Care District has approved the Elixir study (reference number 7 U/2012). All participants gave written informed consent before taking part in this study.
: Not applicable.
: T.M. is currently an employee and stockowner of Firstbeat Technologies Ltd., Jyväskylä, Finland. At the time that the Elixir intervention study was designed and conducted, he worked at the University of Jyväskylä. He did not participate in data analysis or writing the conclusions. No other conflicts of interest are declared by the authors.
